ArticleClinical and translational radiation oncology2026
Multimodal conservative local treatment based on combined brachytherapy and external beam radiation therapy for paediatric pelvic and perineal rhabdomyosarcoma.
Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: In pediatric pelvic or perineal rhabdomyosarcoma, organ preservation rates are high following neoadjuvant chemotherapy. We assessed the impact of combining external beam radiation therapy (EBRT) and brachytherapy (BT) on local control and functional outcomes. Methods: We retrospectively analyzed records of all children who received both EBRT and a BT boost in our department from 2005 to 2023. Data collected included tumor relapse, local control, survival and late toxicity rates. Treatment was administered as part of a multimodal conservative radio-surgical approach. Results: Eighteen patients were identified, with a median age of 4 years (range, 2.9 - 8.6 years). According to the Intergroup Rhabdomyosarcoma Study (IRS) risk groups, 10 patients were classified as IRS-III and 8 as IRS-IV. Seven patients had metastases at diagnosis. The median number of chemotherapy cycles prior to local treatment was 8 (range, 5-10). Nine patients (50 %) underwent prior conservative surgery, followed by radiation therapy consisting of both BT and EBRT. This combination was indicated for at least one the following reasons: nodal invasion (n = 11, 61 %), risk of peritoneal dissemination (n = 3, 17 %) and/or local extension (n = 7, 39 %). The median prescribed dose was 20 Gy (range 12-30 Gy) for BT and 50.4 Gy (range, 18.8-55 Gy) for EBRT. Two patients were treated with HDR BT, while the remaining received LDR (n = 4) or PDR (n = 12).The median follow-up period was 4.6 years (range, 2.9-6.6 years). At the last follow-up, failure free-survival was 67 %, local control was 78 % and overall survival was 83 %. Four patients experienced grade II late urinary toxicities, including dysuria or incontinence in two patients. One patient required secondary cystectomy, and another received botulinum toxin injections in the bladder neck. Conclusion: Organ preservation with favorable functional outcome can be achieved in pelvic and perineal rhabdomyosarcoma by combining BT and EBRT, with or without prior surgery. This approach requires close collaboration to develop customized radiation therapy plans. Extended follow-up is necessary to assess long-term functional outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.